2024
Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma
Matei D, Enserro D, Randall M, Mutch D, Small W, DiSilvestro P, Spirtos N, O’Malley D, Cantuaria G, Michelin D, Waggoner S, Shahin M, Guntupalli S, Lara O, Ueland F, Warshal D, Bonebrake A, Tewari K, Tan A, Powell M, Walker J, Santin A, Kim J, Miller D. Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma. Journal Of Clinical Oncology 2024, 43: 1055-1060. PMID: 39700442, PMCID: PMC11908887, DOI: 10.1200/jco.24.01121.Peer-Reviewed Original ResearchConceptsRecurrence-free survivalRandomized phase III trialOverall survivalC-RTFederation of Gynecology and Obstetrics (FIGOInternational Federation of Gynecology and Obstetrics (FIGOFollow-upIncreased recurrence-free survivalLocally advanced endometrial cancerLocally advanced endometrial carcinomaRate of local recurrenceLymph-vascular space invasionLong-term follow-upGross residual diseaseStratified hazard ratioProbability of OSAdvanced endometrial cancerMedian Follow-UpAdvanced endometrial carcinomaKaplan-Meier methodPhase III trialsBody mass indexMedian OSOS benefitPositive cytology
2012
Cost Comparison of Radiation Treatment Options After Lumpectomy for Breast Cancer
Greenup R, Camp M, Taghian A, Buckley J, Coopey S, Gadd M, Hughes K, Specht M, Smith B. Cost Comparison of Radiation Treatment Options After Lumpectomy for Breast Cancer. Annals Of Surgical Oncology 2012, 19: 3275-3281. PMID: 22851048, DOI: 10.1245/s10434-012-2546-5.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBrachytherapyBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, Intraductal, NoninfiltratingCarcinoma, LobularCombined Modality TherapyCosts and Cost AnalysisFemaleFollow-Up StudiesHealth Care CostsHumansMastectomy, SegmentalMiddle AgedNeoplasm GradingNeoplasm InvasivenessPrognosisRetrospective StudiesConceptsWhole breast radiation therapyBreast cancerRT optionsExternal-beam partial breast irradiationLeukemia Group B 9343MethodsAn institutional review boardResultsMedian patient ageCurrent Procedural Terminology codesMedian tumor sizeInvasive ductal cancerSitu breast cancerPartial breast irradiationProcedural Terminology codesRadiation treatment optionsInstitutional review boardC-RTBackgroundRadiation therapyRT regimensBreast conservationDuctal cancerLobular cancerMixed histologyPatient ageRetrospective reviewTumor histology
2000
Effects of concurrent cisplatinum administration during radiotherapy vs. radiotherapy alone on the immune function of patients with cancer of the uterine cervix
Santin A, Hermonat P, Ravaggi A, Bellone S, Roman J, Pecorelli S, Cannon M, Parham G. Effects of concurrent cisplatinum administration during radiotherapy vs. radiotherapy alone on the immune function of patients with cancer of the uterine cervix. International Journal Of Radiation Oncology • Biology • Physics 2000, 48: 997-1006. PMID: 11072156, DOI: 10.1016/s0360-3016(00)00769-0.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsCisplatinCombined Modality TherapyFemaleHumansImmunity, CellularInterferon-gammaInterleukin-2Killer Cells, NaturalLymphocyte ActivationLymphocyte SubsetsMembrane GlycoproteinsMiddle AgedPerforinPore Forming Cytotoxic ProteinsProspective StudiesReceptors, Interleukin-2Uterine Cervical NeoplasmsConceptsT cellsIL-2Lymphoblast transformationRadiation therapyImmune functionNatural killer cytotoxic activityCD25-positive lymphocytesRadiation-induced immunosuppressionPercentage of CD8Advanced cervical cancerT cell numbersNatural killer cellsT cell subsetsActivation markers CD25C-RTMean absolute numberB cell numbersK562 cellsCisplatinum administrationConcurrent cisplatinumLymphocyte subsetsNK cellsConcurrent administrationKiller cellsUterine cervix
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply